Stereotactic Body Radiation Therapy Versus Fractionated Radiation Therapy for Early-Stage Bronchopulmonary Carcinoid

Abstract

Aim: To compare trends and outcomes in early stage bronchopulmonary carcinoid (BPC) tumors treated nonoperatively with conventionally fractionated radiotherapy (CFRT) and stereotactic body radiotherapy (SBRT). Methods/materials: We queried the National Cancer Database for primary (typical) BPC staged cT1-2N0M0 and treated nonsurgically with lung-directed radiation and ≥1 month of follow-up. Odds ratios were used to predict likelihood of SBRT treatment and multivariable Cox regression determined predictors of survival. Results: Out of 154 patients, 84 (55%) were treated with SBRT and the remainder were treated with CFRT. Although SBRT use was 0% from 2004 to 2007, it varied from 50 to 70% per year thereafter. Propensity-matched Kaplan–Meier analysis revealed improved survival with lung SBRT (median: 66 vs 58 months; p = 0.034). Conclusion: SBRT for early stage, primary BPC has increased over time and was associated with higher survival than CFRT.

A multidisciplinary approach to the work up and management of pulmonary carcinoid tumors and DIPNECH: a narrative review

“…A national cancer database analysis evaluated outcomes in patients with TCs treated with SBRT and conventionally fractionated therapy ( 104 ). Of 154 included patients, 84 received SBRT (median dose of 50 Gy in 4 fractions) while 70 received conventional therapy (median dose of 54 Gy in 24 fractions).…”

The Role of Conventionally Fractionated Radiotherapy and Stereotactic Radiotherapy in the Treatment of Carcinoid Tumors and Large-Cell Neuroendocrine Cancer of the Lung

“…There was an improvement in OS in patients receiving SBRT vs. CFRT (median 66 vs. 58 months). The summary presents the conclusion that SBRT can be considered the preferred form of therapy in inoperable patients [ 86 ].…”